Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.

Stratos Wealth Partners LTD. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 2.5% during the ...

Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it ...

Barclays lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $118 and keeps an Underweight rating on the shares. The firm ...

Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 ...

Zimmer Biomet said on Tuesday it would acquire medical device company Paragon 28 for about $1.1 billion to expand its ...

Q4 2024 Earnings Call Transcript February 6, 2025 Zimmer Biomet Holdings, Inc. beats earnings expectations. Reported EPS is ...

Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the ...

Zimmer Biomet agrees to acquire Paragon 28 for $1.1 billion, with a non-tradeable CVR up to $1 per share. Deal expected to ...

Zimmer Biomet (NYSE: ZBH) shares dipped slightly today on fourth-quarter results that came in just ahead of the consensus ...

Zimmer Biomet made a major play in the foot and ankle treatment space today, announcing it will spend $1.2 billion to acquire ...